(Country; Symbol)

(Country; Symbol)


Terms/Details (Date)

Pharmaceuticals Inc.*

Amarin Development AB (Sweden; subsidiary of Amarin Corp. plc; UK; AMRN)


Amarin will provide pharmaceutical formulation and manufacturing services for Acadia; ACP- 03 is in Phase I studies for neuropsychiatric and neurological disorders (6/18)

BioSciences Inc.

Research and Diagnostic
Systems Inc.*
(subsidiary of
Techne Corp.)

R&D System's reagents with Aclara's eTag Assay System

R&D Systems will supply Aclara with certain reagents, including cytokines and related proteins and antibodies that are being incorporated into the eTag Assay System (5/21)

Agencourt Biosciences

Lucigen Corp.*

CloneSmart cloning kits and research products

Agencourt will distribute Lucigen's kits and products in North America; Lucigen will continue to sell directly to those markets; it transferred to Agencourt certain new product rights arising from its Single Cell Genomics gene discovery libraries in return for in-kind genomic sequencing services provided by Agencourt and undisclosed financial payments (5/27)

BD Biosciences (unit of Becton, Dickinson and Co.; NYSE:BDX)

Open Biosystems*

BD Creator gene cloning and expression system

Open Biosystems was granted a worldwide, nonexclusive license to make, use and sell clone sets in the BD Creator technology format (5/14)

Boston Biomedica Inc. (BBII)

Ambion RNA Diagnostics*
(division of Ambion Inc.)

Ambion's Armored RNA and RunReady products

Boston Biomedica will sell the products through its diagnostics unit (4/29)

Cellegy Pharmaceuticals Inc. (CLGY)

Neopharm Ltd.* (Israel)

Tostrex gel

Neopharm will be the exclusive distributor of Tostrex gel in Israel; it also will file for approval using an existing regulatory package supplied by Cellegy (5/28)

Hawaii Biotech Inc.* Meridian Bioscience

Viral Antigens Inc. (subsidiary of dengue Inc.; VIVO)

Bulk polyvalent recombinant subunit vaccine for virus 1-4

Viral Antigens will manufacture and supply the vaccine (6/10)

InKine Pharmaceutical
Co. Inc.

Paladin Labs Inc. (Canada; TSE:PLB)


Paladin Labs licensed the exclusive rights to register, sell, market and distribute Visicol for use in Canada; Paladin paid an undisclosed up-front license fee and will pay royalties to InKine on future sales of Visicol; Paladin will be responsible for all costs (5/21)

MDS Sciex
(division of MDS Inc.; Canada; NYSE:MDZ)

SC BioSciences Corp.* (Japan)

NanoLC Proteomics

Exclusive distributorship agreement to deliver MDS Sciex's NanoLC Proteomics system in Japan (6/9)

Nastech Pharmaceutical
Co. Inc.

Questcor Pharmaceuticals Inc. (AMEX:QSC)


Questcor is paying up to $18.2M for rights to the approved drug Nascobal, a product for multiple sclerosis and inflammatory bowel disease (6/17)

NovaScreen Biosciences Corp.*

Tripos Inc. (TRPS)

Tripos' LeadScreen compound plates and LeadQuest libraries; NovaScreen's assay development, HTS reagents, HTS services, secondary screening and in vitro ADME/Tox screening

Mutual service and distribution agreement that will allow each company's sales force to offer the other's products and services to its biotechnology and pharmaceutical clients (6/18)

Orchid BioSciences Inc. (ORCH)

Genetic Technologies Ltd. (Australia; OTC BB: GNTLF; ASX:GTG)

Exclusive licensing agreement for Orchid's SNP panels for paternity and forensic DNA testing services for Australia, New Zealand and Southeast Asia

Genetic Technologies also receives an exclusive license to market, distribute and sell Orchid's Elucigene range of diagnostic kits for genetic testing in those territories, as well as a nonexclusive license in the field of diagnostics to certain primer extension patents; Orchid receives an option to license Genetic Technologies' non-coding patents for SNP analysis; it will receive royalties on revenues generated from its SNP-based technologies (5/30)

OSI Pharmaceuticals Inc. (OSIP)

Celgene Corp. (CELG)


OSI gained full rights to market and promote Gelclair in the North American oncology setting; it gained the rights through its acquisition of Cell Pathways Inc., which had a co-promotion agreement with Celgene (6/13)

PamGene International BV* (the Netherlands)

Olympus Optical Co. Ltd.* (Japan)

PamGene's flow-through microarray technology

Olympus paid |6M (US$7M) for the nonexclusive worldwide right to sell the product (5/7)

Pharmasset Inc.*

Primagen Holding BV* (the Netherlands)

A mitochondrial DNA detection and toxicity technology

The agreement is for an exclusive worldwide license to commercialize the technology developed by Pharmasset (4/28)

Pharmexa A/S (Denmark; CSE:PHARMX)

Xenova Group plc (UK; XNVA; LSE:XEN)

A vaccine targeting the human HER-2 protein

Xenova signed a two-year manufacturing, development and clinical supply agreement with Pharmexa for the contract manufacture of clinical supplies of the vaccine (6/5)


# The information in the chart does not cover agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copehnhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange.